One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets.

APRIL, a leading skincare and fragrance chain in Israel, secures exclusive rights to Escentric Molecules, a gender-free ...

Pfizer's most advanced candidate, a molecule called danuglipron, has had a rough go at it, with middling efficacy and several ...

Ixekizumab and apremilast may be an effective treatment among patients with genital psoriasis, with improved disease response and clearance rates.

I believe in science.  The Earth is a sphere, orbiting the Sun, and the climate crisis is real, already destroying our economy.  Trump and his MAGA followers believe it is all a hoax.  Everything ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $10.00. The ...

This week got off to a flying start when new science experiments and cargo were launched to the International Space Station, ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer Experienced CFO and investment banker with 30-year track record will ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, Ratings reports. Two research analysts have ...

Needham & Company LLC reiterated their buy rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report issued on Wednesday morning, Benzinga reports. Needham & Company LLC ...